Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | DBH | P09172 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6683778 | 0.88 | PARP1 (0.39) | PARP1PARP2SMN1; SMN2 | |
| SCHEMBL6678347 | 0.84 | ALDH1A1 (0.43) | LIPGSMN1; SMN2 | |
| SCHEMBL6683313 | 0.81 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL6664787 | 0.79 | FEN1 (0.31) | LIPGDBH | |
| SCHEMBL7063524 | 0.79 | LIPG (0.31) | LIPGDBH | |
| SCHEMBL6677757 | 0.74 | ABCB1 (0.37) | SMN1; SMN2 | |
| SCHEMBL6679671 | 0.72 | MMP1 (0.40) | SMN1; SMN2 | |
| SCHEMBL6664325 | 0.72 | TRPA1 (0.46) | LIPGSMN1; SMN2 | |
| SCHEMBL6666868 | 0.72 | P2RX7 (0.31) | SMN1; SMN2 | |
| SCHEMBL6681187 | 0.69 | PTGS1 (0.35) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | claimed |
| WO-2004014921-A1 | 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | PARP1 112/4885PARP2 597/4885LIPG 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.